NCT06653322View on ClinicalTrials.gov

A Multi-centered，Randomized，Double-blind，Placebo-controlled Study to Evaluate the Efficacy and Safety of SHR-1703 in Eosinophilic Asthma

PHASE3RecruitingINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

November 21, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

December 31, 2027

Conditions
Asthma With Eosinophilic Phenotype
Interventions
DRUG

HR-1703

HR-1703 will be administered by SC injection.

DRUG

Placebo

Matching Placebo will be administered by the SC injection.

Trial Locations (1)

610041

RECRUITING

West China School of Medicine West China Hospital of Sichuan University, Chengdu

All Listed Sponsors
lead

Guangdong Hengrui Pharmaceutical Co., Ltd

INDUSTRY